These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

73 related items for PubMed ID: 15778099

  • 1. Interferon beta, progressive MS, and brain atrophy.
    Chaudhuri A.
    Lancet Neurol; 2005 Apr; 4(4):208-9. PubMed ID: 15778099
    [No Abstract] [Full Text] [Related]

  • 2. Does interferon beta help in secondary progressive MS?
    Cohen JA, Antel JP.
    Neurology; 2004 Nov 23; 63(10):1768-9. PubMed ID: 15557486
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. MRI and assessment of treatment in multiple sclerosis.
    Miller DH, Thompson AJ, Kappos L.
    Brain; 2001 May 23; 124(Pt 5):1052-3. PubMed ID: 11335707
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [A meta-analysis of interferon-beta in the secondary progressive multiple sclerosis].
    Fan X, Yang L.
    Zhonghua Yi Xue Za Zhi; 2009 Jun 02; 89(21):1484-9. PubMed ID: 19953902
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW, CHOICE investigators.
    Lancet Neurol; 2010 Apr 02; 9(4):381-90. PubMed ID: 20163990
    [Abstract] [Full Text] [Related]

  • 9. [Beta-interferon clinical trials using MRI in patients with multiple sclerosis].
    Lebrun C.
    Rev Neurol (Paris); 2001 Sep 02; 157(8-9 Pt 1):761-7. PubMed ID: 11677396
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Seeing injectable ms therapies differently: they are more similar than different.
    Johnson KP, Fox RJ, Arnold DL.
    Neurology; 2010 Feb 23; 74(8):702. PubMed ID: 20177129
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a.
    Dubois B, Leary SM, Nelissen I, Opdenakker G, Giovannoni G, Thompson AJ.
    J Neurol; 2003 Sep 23; 250(9):1037-43. PubMed ID: 14504963
    [Abstract] [Full Text] [Related]

  • 16. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
    Nadeau SE.
    Neurology; 2006 May 09; 66(9):1457-8; author reply 1457-8. PubMed ID: 16682694
    [No Abstract] [Full Text] [Related]

  • 17. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N, Weinstock-Guttman B.
    Mult Scler; 2012 Aug 09; 18(8):1125-34. PubMed ID: 22194217
    [Abstract] [Full Text] [Related]

  • 18. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP, Rovaris M, Comi G, Filippi M.
    Neurology; 2009 Nov 10; 73(19):1538-42. PubMed ID: 19794123
    [Abstract] [Full Text] [Related]

  • 19. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
    Kieseier BC, Hartung HP.
    Exp Neurol; 2007 Jan 10; 203(1):1-4. PubMed ID: 17069803
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.